Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zangdong He

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 22, 2008
No genetic association between polymorphisms in the kainate-type glutamate receptor gene, GRIK4, and schizophrenia in the Chinese populationZhiqiang Li, Zangdong He, Wei Tang, et al.
Schizophrenia Research|February 26, 2008
The Ser9Gly polymorphism of the dopamine D3 receptor gene and risk of schizophrenia: an association study and a large meta-analysisGang Ma, ZangDong He, WenLi Fang, et al.
Journal of Psychiatric Research|March 21, 2007
No significant association between the genetic polymorphisms in the GSK-3 beta gene and schizophrenia in the Chinese populationJunwei Meng, Yongyong Shi, Xinzhi Zhao, et al.
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Human Molecular Genetics|April 21, 2011
A genome-wide association study reveals association between common variants in an intergenic region of 4q25 and high-grade myopia in the Chinese Han populationZhiqiang Li, Jia Qu, Xun Xu, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 22, 2008
No genetic association between polymorphisms in the kainate-type glutamate receptor gene, GRIK4, and schizophrenia in the Chinese populationZhiqiang Li, Zangdong He, Wei Tang, et al.
Schizophrenia Research|February 26, 2008
The Ser9Gly polymorphism of the dopamine D3 receptor gene and risk of schizophrenia: an association study and a large meta-analysisGang Ma, ZangDong He, WenLi Fang, et al.
Journal of Psychiatric Research|March 21, 2007
No significant association between the genetic polymorphisms in the GSK-3 beta gene and schizophrenia in the Chinese populationJunwei Meng, Yongyong Shi, Xinzhi Zhao, et al.
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Human Molecular Genetics|April 21, 2011
A genome-wide association study reveals association between common variants in an intergenic region of 4q25 and high-grade myopia in the Chinese Han populationZhiqiang Li, Jia Qu, Xun Xu, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Pageof 2